Pazopanib has too many side effects

Pazopanib(Pazopanib) is an oral tyrosine kinase inhibitor registered for metastatic renal cell carcinoma and soft tissue sarcoma. Liver toxicity is a common side effect of this class of drugs. Current opinion is that in the event of severe hepatotoxicity, pazopanib treatment should be interrupted and restarted at a lower dose upon return to Common Terminology Criteria for Adverse Events (CT CAE) grade 1. After recurrence of hepatotoxicity at lower doses, permanent discontinuation of pazopanib is recommended.

Hepatotoxicity is a well-known side effect of pazopanib. In the PALETTE study, the incidence of ≥ grade 2 elevations in alanine aminotransferase (ALAT) was 10% and that of aspartate aminotransferase (ASAT) was 8%. In the study of renal cell carcinoma (RCC), grade ≥3 increases were found in 12% in ALAT, 7% in ASAT, and 3% in total bilirubin, and two patients were assessed to have died due to abnormal liver function. Physicians should use caution when prescribing pazopanibin patients with abnormal ASAT, ALAT, and total bilirubin levels and should at least temporarily discontinue treatment when grade 3 or above increases occur during treatment. If liver function abnormalities recur after treatment is restarted, pazopanib should be permanently discontinued.

PazopanibThe original drug has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be around 3,000 yuan. The price of pazopanib original drug specifications200mg*30 tablets marketed overseas may be around 1,000 RMB per box (the price may fluctuate due to exchange rates). There are also pazopanib generic drugs produced in other countries. The price of 200mg*30 tablets produced by Bangladesh pharmaceutical factory may be around 500 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.